Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ctDNA testing · 1 trial · 1 indication
RFS is defined as the time from the date of cystectomy in ctDNA-negative MIBC participants to the date of first documented radiological recurrence per RECIST v1.1 or death, whichever occurs first.
| Arm | Type | Description |
|---|---|---|
| ctDNA-negative MIBC | EXPERIMENTAL | There will be a pilot lead-in phase for the first 30 participants who are eligible due to the risks associated. Participants who are newly diagnosed with MIBC who are candidates for radical cystectomy will undergo baseline ctDNA test. Participants who are confirmed to be ctDNA negative will be enrolled in the study and will proceed directly to radical cystectomy without neoadjuvant chemotherapy (NAC). After surgery, participants will undergo standard of care assessments. |
| Name | Type | Description |
|---|---|---|
| ctDNA testing | DIAGNOSTIC_TEST | Newly diagnosed MIBC participants who are candidates for radical cystectomy will first undergo baseline ctDNA testing to see if they are ctDNA negative. If the participant is confirmed ctDNA negative, they will be enrolled in the study and undergo radical cystectomy without neoadjuvant chemotherapy. |
Inclusion Criteria: * Histologically confirmed muscle-invasive urothelial carcinoma of the bladder (cT2- T4aN0M0). * Planned for radical cystectomy with curative intent. * Negative for ctDNA using a validated, tumor-informed assay (Natera Signatera) from a blood sample collected prior to any system...